The expression of a E b 7 integrin has been related to the selective retention of lymphocytes in mucosal tissues of gut, urogenital tract and lung. To identify potential disease-associated a E b 7 expression patterns on cells accounting for lymphocytic alveolitis in interstitial lung disease (ILD), a E expression on CD4 þ and CD8 þ T cell subsets was evaluated by dual-colour flow cytometry in peripheral blood and bronchoalveolar lavage fluid (BALF) of patients with idiopathic pulmonary fibrosis (IPF; n ¼ 18), hypersensitivity pneumonitis (HP; n ¼ 20) and sarcoidosis (n ¼ 44) in comparison with healthy controls (n ¼ 15). In both healthy individuals and all patient groups the proportion of a E -bearing T cells in peripheral blood was < 2%, whereas the vast majority of alveolar CD8 þ T cells consistently coexpressed a E . Absolute alveolar CD8 þ a Eþ cell numbers/ml were up to 30-fold increased in HP patients. Proportions of a E -bearing CD4 þ cells in BALF were significantly elevated in IPF (74·0 Ϯ 2·7%) and HP (70·0 Ϯ 2·4%) compared with normals (30·0 Ϯ 1·8%) (mean Ϯ s.e.m.; P < 0·01). In sarcoidosis, the a E expression on BALF CD4 þ cells displayed subgroup dependency: proportions significantly lower than normal were noted in chest radiographic stage I (14·3 Ϯ 1·5%), but increased proportions in stages II (50·0 Ϯ 3·8%) and III (64·0 Ϯ 4·8%). Correlations between common markers of T cell activation or BALF transforming growth factor-beta (TGF-b ) bioactivity and a E expression were not noted. We conclude that the vast majority of alveolar CD8 þ T cells consistently express a E b 7 and that distinct patterns of a E b 7 expression on alveolar CD4 þ lymphocytes in sarcoidosis are related to the diverse manifestations of the sarcoid inflammatory process in the lung.
INTRODUCTION
The integrin b 7 -chain associates with two a-chains, a 4 (CD49d) and a E (CD103), to form a heterodimer involved in cell adhesion [1] . The expression of both members of the b 7 family is mainly restricted to lymphocyte subsets: the a 4 b 7 heterodimer is expressed on circulating T cells and mediates adhesion to a mucosal structure called MadCAM-1 which is likely to be important during lymphocyte homing to Peyer's patches [2] ; in contrast, a E b 7 is found on the surface of intraepithelial and lamina propria lymphocytes in mucosal tissues with < 2% frequency on circulating peripheral blood lymphocytes [3, 4] . The expression of the site-specific a E b 7 integrin, first described as human mucosal antigen-1 (HML-1), on T cells within or adjacent to the epithelium of the gut [5, 6] has been related to the compartmentalization and retention of immune reactive cells to the gut mucosa [7, 8] . Recently, E-cadherin expressed on the basolateral surface of epithelial cells has been identified as one counter-receptor for a E b 7 [9, 10] . In addition, human a E b 7 and its rat and mouse homologues are expressed on intraepithelial lymphocytes in mucosal areas of the urogenital tract and the lung [11, 12] . In particular, a significant proportion of lymphocytes, predominantly of the CD8 þ subset, derived from the alveolar space of normal individuals was found to express the a E b 7 integrin [13] . In interstitial lung disease (ILD) selected T cell subsets are known to accumulate in the alveolar space associated with profound changes of alveolar cytokines [14] such as transforming growth factor-beta (TGF-b), which has been related to both a E b 7 induction on T cells [4] and progressive lung fibrosis [15, 16] . We hypothesized that T cells accounting for the lymphocytic alveolitis in patients with ILD display distinct disease-associated a E b 7 expression patterns potentially related to alveolar TGF-b levels. Therefore a representative panel of patients with idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP) and sarcoidosis was evaluated for the expression of a E b 7 on T cells in paired samples of peripheral blood and lung epithelial lining fluid and for alveolar levels of TGF-b bioactivity.
PATIENTS AND METHODS

Study population
Eighty-two spontaneously breathing patients (age 18-78 years) with ILD, non-treated at the time of initial lavage, were recruited into the study over a period of 3 years. The patients were compared with 15 healthy control subjects (age 18-55 years; six female, nine male, 10 non-smokers, two ex-smokers, three current smokers) without a history of cardiac or pulmonary disease, normal chest radiographs and pulmonary function testing. The study protocol was approved by the local ethics committee and informed consent was obtained from each subject before entry into the study. Classification into IPF, HP and sarcoidosis of different chest radiographic stages was performed according to the following criteria: IPF (n ¼ 18): unknown aetiology; restrictive pattern in pulmonary function in combination with reduced pulmonarydiffusing capacity for carbon monoxide (DL CO ); typical findings in chest x-ray or computed tomography (CT/HRCT); increased neutrophil counts in bronchoalveolar lavage fluid (BALF), which may be accompanied by an elevated percentage of lymphocytes or eosinophils; interstitial pneumonitis with interstitial fibrosis with no evidence of granulomas, vasculitis, or inorganic material in lung biopsy; HP (n ¼ 20): proof of an inhalative antigen (history of periodically recurring or permanent exposure-dependent complaints) in combination with the detection of precipitating antibodies; patchy interstitial infiltration of both lungs in chest x-ray or CT/HRCT; elevated BAL lymphocyte counts with mostly decreased CD4/CD8 ratio; typical histological finding in lung biopsy; sarcoidosis (n ¼ 44): abnormal chest radiograph (bilateral hilar adenopathy, without (stage I, n ¼ 20) or with (stage II, n ¼ 11) pulmonary infiltrates such as coarse reticulonodules or fluffy cotton wool confluent shadows; infiltrates without hilar adenopathy (stage III, n ¼ 13)); elevated BAL lymphocyte counts with mostly increased CD4/CD8 ratio; typical non-caseating epithelioid cell granuloma in transbronchial lung biopsy; stage I patients with Löfgren's syndrome (n ¼ 7) were regarded as a separate subgroup. Characteristics of all study populations are outlined in Table 1 .
Bronchoalveolar lavage
BAL was performed in spontaneously breathing subjects during routine flexible bronchoscopy as previously described [17] . The distal end of the bronchoscope was wedged into a segment bronchus of the right middle lobe or the lingula. Ten 20-ml portions of sterile 0·9% saline were instilled, aspirated, cooled to 4ЊC and pooled. The overall fluid recovery ranged between 55% and 70%. Lavage fluids were filtered through sterile gauze, immediately placed on ice and cells were separated by centrifugation at 200 g for 10 min at 4ЊC. The aliquoted supernatant was subsequently frozen and kept at -80ЊC until further use. Cells were counted with a haemocytometer, viability was assessed by trypan blue exclusion (0·5% w/v in PBS; Sigma, St Louis, MO), and differential cell counting was performed in Pappenheim-stained cytocentrifuge preparations (May-Grünwald and Giemsa solution; Merck, Darmstadt, Germany). In parallel to the BAL procedure, mononuclear cells were obtained from heparinized samples of peripheral venous blood on a Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient as described by Böyum [18] .
Flow cytometry
The phenotype of lung and blood lymphocytes was determined by immunofluorescence and flow cytometry as previously described [17] using the FITC-or PE-conjugated mouse MoAbs b-ly7 (CD103) (Biermann, Bad Nauheim, Germany), FIB504 (integrin b 7 ) (Pharmingen, San Diego, CA), Leu-3a (CD4), Leu-2a (CD8a), anti-HLe-1 (CD45), Leu-M3 (CD14), L243 (MHCII/DR), 2A3 (CD25), Leu-23 (CD69) (all purchased from Becton Dickinson, San Jose, CA), AC2 (CD39), 84H10 (ICAM-1, CD54), IgG1, IgG2a and IgG2b isotype controls (all from Dianova, Hamburg, Germany), Tue169 (MHCII/DQ) (Pharmingen). Mononuclear peripheral blood or BALF cells (2 × 10 5 ) were incubated in the -smoker  2  3  0  2  2  3  Current smoker  6  5  1  3  3 
* Dyspnoea was individually scored by each patient on a scale from 0 to 4.
presence of saturating amounts of fluorochrome-labelled MoAbs in flexible round-bottomed microtitre plates (Dynatech, Nuertingen, Germany) on ice for 30 min with occasional shaking. After two washes with PBS containing 0·1% bovine serum albumin (BSA; Behring, Marburg, Germany) and 0·02% NaN 3 (PBS-BSA-NaN 3 ), cells were analysed on a FACScan flow cytometer (Becton Dickinson). Daily calibration of fluorescence intensity was performed with standardized calibration beads and Auto-COMP software (Becton Dickinson). Lymphocytes were gated by dual light scatter characteristics with gate checking using CD45-FITC/CD14-PE (Leukogate; Becton Dickinson). Fluorescence distribution properties (using 4-decade logarithmic amplifiers) were recorded for 10 4 events, collected in list mode data files on FACScan research software and further analysed using the PC-Lysys research software (Becton Dickinson). Quadrant plots of fluorescence 1 versus fluorescence 2 were used to determine numbers of a E -bearing cells as percentages of CD4 þ and CD8 þ lymphocytes. Corresponding absolute numbers/ml of the respective T cell subsets in BALF were calculated from the total BALF leucocyte count per microlitre and the differential counts as described for peripheral blood [19] .
Assay for TGF-b
To assess biologic activity of TGF-b in BALF, we used an assay based on the growth-inhibition of mink-lung epithelial cells (Mv 1 Lu, CCL-64; American Type Culture Collection, Rockville, MD) [20] . Briefly, subconfluent CCL-64 cells were trypsinized and plated at 1 × 10 4 cells in 0·1 ml/well in 96-well plates (Nunc, Nuertingen, Germany). Aliquots of BALF samples that had been acidified and subsequently neutralized were applied with or without addition of a polyclonal anti-TGF-b antibody (Biermann Ltd, Bad Nauheim, Germany). To quantify the percentage of TGF-b released in its active form, TGF-b activity was measured without preceding acidification in an additional series. After 22 h, inhibition of proliferation of CCL-64 cells was measured by MTT assay as described previously [21] . A standard curve of human recombinant TGF-b (R&D Systems, Minneapolis, MN) was included in each assay.
Statistical analysis
Data are expressed as mean Ϯ s.e.m., median values are additionally displayed. Statistical evaluation of differences between healthy controls and patient groups was performed by applying the Kruskal-Wallis H-test and the Wilcoxon-Mann-Whitney test. For interpretation of multiple comparisons, the Bonferroni correction was considered. P < 0·05 was considered significant.
RESULTS
While the a E surface molecule, which was always found to be co-expressed with b 7 in dual-colour staining experiments, was detectable on < 2% of peripheral blood T cells in both normal individuals and all patient groups (data not shown), distinct a E expression patterns could be identified on BALF CD4 þ and CD8 þ lymphocytes shown as representative cytograms for controls, IPF, HP and sarcoidosis patients in Fig. 1 . The vast majority of CD8 þ lymphocytes was stained by anti-a E antibodies without significant differences in mean and median CD8 þ a Eþ cell proportions between normals (n ¼ 15) and patients with IPF (n ¼ 18), HP (n ¼ 20), or sarcoidosis (n ¼ 44) ( Fig. 2a ). Absolute numbers/ml of CD8 þ a Eþ cells, however, were increased in all patient groups in comparison with healthy controls, most pronounced in HP with a > 30-fold alveolar accumulation of this subset ( Table 2) . In contrast to CD8 þ cells, the proportion of alveolar CD4 þ cells co-expressing a E showed significant differences between the various patient groups and controls ( Fig. 2a ). Thus, in IPF and HP the mean and median percentages of a E -bearing CD4 þ cells were significantly higher than the levels found in normal volunteers (median values 74·5% (range 55-95%) and 67·1% (range 54·5-86·2%) versus 28·0% (range 20·8-26·5%), respectively; P < 0·01). In the mixed sarcoidosis group, including patients in all radiographic stages, the mean and median percentages of a E -expressing CD4 þ BALF lymphocytes did not significantly differ from normal values. Subgroup analysis did, however, show that the frequency of a E expression on the expanded CD4 þ BALF lymphocyte subset varied to a great extent. Lower frequencies of a E than normal were noted in sarcoidosis I with or without Löfgren's syndrome (median values 9·9% (range 6·3-19·7%) and 16·0% (range 5·9-27·0%), respectively), and significantly elevated frequencies compared with normals were observed in sarcoidosis II (50·0% (range 29-74%)) and in sarcoidosis III (64% (range 36·2-94%))
᭧ 1999 Blackwell Science Ltd, Clinical and Experimental Immunology, 116:340-346 ( Fig. 2b) . When BALF T cell subsets of all study groups were examined for the expression of surface molecules described as early and late T cell activation markers like HLA-DR, HLA-DQ, CD25, CD39, CD54, and CD69, we did not detect a significant correlation of a E integrin expression to any of the other T cell activation markers analysed (data not shown).
Since TGF-b is known to be a potent inducer of a E on peripheral blood T cells in vitro, TGF-b bioactivities in BALF of all study groups were determined by bioassay (Table 3 ). Mean and median values of total TGF-b bioactivity were not significantly different between normals and patient groups, arguing against a relationship of total BALF TGF-b bioactivity levels to the induction of a E on alveolar CD4 þ cells. In contrast, mean and median proportions of in vivo activated TGF-b in relation to total TGF-b induced by in vitro acidification were significantly elevated in all patient groups compared with normals (median value 45·2% (range 33·7-65·2%)), and moreover to a significantly higher extent in IPF (median value 89·8% (range 70·2-100%)) as well as sarcoidosis stage II (median value 91·1% (range 63·2-100%)) and III (median value 92·5% (range 81·1-100%)) when compared with Löfgrens's syndrome (median value 64·5% (range 50·5-84·8%)) or sarcoidosis stage I (median value 73% (range 60·4-98·6%)). However, correlations between amount or proportion of activated TGF-b bioactivity and proportions or absolute numbers of a E -expressing lymphocyte subsets within groups did not reach statistical significance (data not shown). A narrow and highly specialized pattern of a E expression, being restricted largely to T cells, particularly CD8 þ cells, within or immediately adjacent to mucosal epithelia, has been observed both in mouse and man [5, 12] , suggesting local induction of a E expression by factors of the mucosal microenvironment. This concept is further supported by data indicating a role of a E not in lymphocyte emigration [22] 
DISCUSSION
Evaluation of a E integrin expression on BALF-derived T lymphocytes from normal individuals and from patients with ILD revealed: (i) a E expression on a high and remarkably constant
Original lavage fluids were analysed for cellularity and cell distribution (%) was assessed in the 200 g pellet (for details see Patients and Methods). Means Ϯ s.e.m. are given throughout. Statistical analysis was performed for all groups in comparison with normal individuals: *P < 0·05; **P < 0·01; ***P < 0·001. 
Values expressed as mean Ϯ s.e.m. and median in parentheses for each group. *P < 0·01 versus healthy controls; ** < 0·001 versus healthy controls; †P < 0·001 versus Löfgren's syndrome; ‡P < 0·05 versus sarcoidosis stage I. lymphocytes in distinct mucosal compartments [7, 8] , probably being operated by E-cadherin which is expressed basolaterally on epithelial cells as one ligand [9, 10] .
Concerning the a E expression on BALF T cell subsets, the mechanisms responsible for its induction, its functional role and further potential ligands in the alveolar space remain to be defined. Our data indicate that special requirements for the induction of the a E integrin chain on T cell subsets seem to be mandatory, since we detected distinct disease-associated patterns on CD4 þ T cells. Moreover, we did not find a correlation between early or late T cell activation markers such as HLA-DR, HLA-DQ, CD25, CD39, CD54, or CD69 and a E expression on peripheral blood or BALF T cells, confirming previous reports [23, 24] . Since the vast majority of CD8 þ BALF T cells co-express a E even in healthy controls, constitutive factors in the pulmonary microenvironment may be sufficient to induce a E on the majority of CD8 þ cells. This observation is also true for the heavily expanded CD8 þ T lymphocyte pool residing in the alveolar space in HP patients.
In contrast, the induction mechanisms of a E on CD4 þ cells are apparently different and dependent on additional stimuli obviously present in HP, IPF and sarcoidosis II/III but not in normals or sarcoidosis stage I. TGF-b has been shown to play a key role in the induction of a E in vitro [4, 22, 25] and it has been suggested that a similar inductive effect operates in vivo in the mucosal microenvironment. Moreover, there is increasing evidence from experimental models and clinical settings to suggest that TGF-b also plays an important role in the pathogenesis of lung fibrosis [15, 16] . When evaluated by bioassay in the present study, total TGF-b levels in BALF were found highest in normals and patients with Löfgren's syndrome, confirming data obtained by Yamauchi et al. [26] for healthy individuals and by Zissel et al. [27] , who demonstrated an increased in vitro TGF-b production of alveolar macrophages from sarcoidosis patients with self-limiting disease. Although levels of TGF-b bioactivity in BALF detectable without activation by acidic treatment in vitro were found elevated in BALF derived from IPF, HP and sarcoidosis II/III, correlations between proportion or absolute counts of a E -expressing BALF lymphocytes and levels of preactivated BALF TGF-b within patient groups did not reach significance. This does not totally exclude a role of TGF-b in the induction of a E on BALF CD4 þ T cells, since BALF levels of TGF-b may not properly reflect microenvironmental TGF-b bioactivity in the lung. TGF-b1 has been shown to be present in high amounts in alveolar epithelial cells in advanced pulmonary fibrosis [15] . However, there may be a role for additional factors with a E induction potency on CD4 þ cells in the lung. Rihs et al. [24] have recently shown that T cell activation by anti-CD3 cross-linking in the presence of TGF-b is sufficient to induce a E on the majority of CD8 þ peripheral blood T lymphocytes in vitro, whereas additional antibody-induced crosslinking of a 4 b 1 integrin was necessary for a E induction on the majority of CD4 þ cells. The relevance of this in vitro finding for the variety of b 1 -integrin-ligand interactions supposed to occur in vivo during lymphocyte transmigration remains to be evaluated.
In the present study the percentage of a E co-expression on CD4 þ cells was able to discriminate not only between normal individuals and patients with ILD but, more importantly, among sarcoidosis patients presenting with hilar adenopathy alone (i.e. radiographic type I) and patients with pulmonary infiltrates (i.e. radiographic types II and III). Although this conventional x-ray categorization of sarcoidosis neither represents consecutive stages of the disease nor reflects the inflammatory process within the lower respiratory tract, it is still related to the extent of tissue damage in the lung parenchyma and, albeit indirectly, to the extent of pulmonary fibrosis [28] . This is reflected by significantly reduced DL CO values in patients with type III sarcoidosis in the present study. Since patients with type I x-rays, in particular patients with Löfgren's syndrome, tend to have acute or subacute, reversible forms of disease, while those with type II and III more often have chronic progressive manifestations, a prognostic significance of the amount of a E co-expression on CD4 þ BALF cells may be assumed. Whether microenvironmental changes associated with the development of lung fibrosis play a role in the induction of a E on alveolar CD4 þ cells in sarcoidosis, or whether alveolar a Eþ T cells themselves are involved in the fibrotic process, remains to be elucidated.
In conclusion, the data presented lend further support for a role of a E integrin not only on mucosal intraepithelial and lamina propria lymphocytes but also on T cells in the alveolar space. The observed differences of a E co-expression on CD4 þ cells between patient groups may reflect variations of the alveolar microenvironment cytokine profile or differences in dynamics and turnover of lymphocytes in ILD-associated alveolitis, which are complex and incompletely understood. In addition, the striking differences of a E co-expression on CD4 þ T cells in sarcoidosis patients with different radiographic stages suggest that analysis of this integrin might be helpful to discriminate between acute self-limiting forms of alveolitis and chronic manifestations with the tendency towards fibrosis, and warrants further studies concerning the prognostic value of a E expression on BALF T cell subsets in sarcoidosis.
